Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 2 × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 49 Lung Neoplasms 12 Neoplasms 8 Lymphoma, Large-Cell, Anaplastic 8 Neoplasm Metastasis 7 Multiple Myeloma 6 Lymphoma 6 Granuloma, Plasma Cell 4 Colorectal Neoplasms 4 Adenocarcinoma 4 Uveal Melanoma 3 Neuroblastoma 3 Melanoma 3 Hematologic Neoplasms 3 Carcinoma, Renal Cell 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Recurrence 2 Glioma 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Breast Neoplasms 2 ALK-positive NSCLC 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1

Interventions

Bevacizumab 5 Everolimus 4 Sirolimus 2 Lapatinib 2 HDAC-42 2 vistusertib 1 temsirolimus 1 neratinib 1 icotinib 1 emvododstat 1 brolucizumab 1 brigatinib 1 aflibercept 1 Vascular Endothelial Growth Factor A 1 Valproic Acid 1 Sunitinib 1 Magnetic Resonance Imaging 1 Immunoglobulin G 1 Exome 1 Endostatins 1 Doxycycline 1 Disulfides 1 Crizotinib 1 Cetuximab 1 Axitinib 1 Aspirin 1 AZD 6244 1 89Zr-bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04283669 2026-03-13

NF110

University of Alabama at Birmingham

Phase 2 Completed

12 enrolled 5 charts

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡